| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Human |
| Target | IL6 |
| Clinical data | |
| ATC code | |
| Identifiers | |
| CAS Number | |
| DrugBank |
|
| ChemSpider |
|
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C6450H9926N1690O1998S46 |
| Molar mass | 144588.95 g·mol−1 |
 N Y (what is this?) (verify) | |
Sirukumab (INN, USAN) (developmental code name CNTO-136, tentative brand name Plivensia) is a human monoclonal antibody designed for the treatment of rheumatoid arthritis.[1] It acts against the proinflammatory cytokine Interleukin 6 (IL-6).[2]
Sirukumab is currently under developmentbyJohnson & Johnson's subsidiary Centocor.[3]
It has started clinical trials.[4] and reported some phase II results.[3]
In December 2015 three phase III trials (SIRROUND-D, -H and -T) were collecting data.[5] By Feb 2017 SIRROUND-D was considered to have met both co-primary endpoints.[6]
The drug was previously under development for the treatment of depression.[7]
|
| |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Intracellular (initiation) |
| ||||||||||||||
| Intracellular (reception) |
| ||||||||||||||
| Extracellular |
| ||||||||||||||
| Unsorted |
| ||||||||||||||
|
| |||||
|---|---|---|---|---|---|
| IL-1 |
| ||||
| IL-2 |
| ||||
| IL-3 |
| ||||
| IL-4 |
| ||||
| IL-5 |
| ||||
| IL-6 |
| ||||
| IL-7 |
| ||||
| IL-8 |
| ||||
| IL-9 |
| ||||
| IL-10 |
| ||||
| IL-11 |
| ||||
| IL-12 |
| ||||
| IL-13 |
| ||||
| IL-15 |
| ||||
| IL-17 |
| ||||
| IL-18 |
| ||||
| IL-20 |
| ||||
| IL-21 |
| ||||
| IL-22 |
| ||||
| IL-23 |
| ||||
| IL-27 |
| ||||
| IL-28 |
| ||||
| IL-31 |
| ||||
| IL1RL1 |
| ||||
| IL1RL2 |
| ||||
| Others |
| ||||
 | This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it. |
 | This antineoplasticorimmunomodulatory drug article is a stub. You can help Wikipedia by expanding it. |
